ANI
12 May 2022, 14:48 GMT+10
Seoul [South Korea], May 12 (ANI/Global Economic): NeoImmuneTech said on the 11th that it has obtained the approval for a phase 2 clinical trial plan that concomitant administration of US Merck's immune checkpoint inhibitor Keytruda and its T-cell amplifier NT-I7 to patients with glioblastoma from the United States FoodDrug Administration (US FDA).
The phase 2 trial will be led by Professor Jian Campian at the US Mayo Clinic. It will evaluate the safety and treatment efficacy. Merck and NeoImmuneTech will supply Keytruda and NT-I7.
The research team expects the concomitant administration of Keytruda and NT-I7 to improve the survival rate of patients with glioblastoma.
The survival time of glioblastoma is less than 6 months, and the prognosis is very poor. Some chemotherapy drugs and a target anticancer Avastin are used for treatment, but the effectiveness is not significant. Genexine is conducting a clinical trial of the concomitant administration of Avastin and Efineptakin Alfa (GX-I7) in Korea, and NeoImmuneTech plans to test immune checkpoint inhibitor and T-cell amplifier. After the phase 2 trial, it will enter the phase 3 trial of the most likely treatment.
NT-I7 is a drug that amplifies T cell immunity to remove cancer cells and infected cells. Currently, it is under clinical development to treat various deadliest cancers and infectious diseases. (ANI/Global Economic)Get a daily dose of North Korea Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to North Korea Times.
More InformationBUENOS AIRES, Argentina: Since taking office in December 2023, Argentine President Javier Milei has implemented sweeping austerity...
LEMBATA, Indonesia: Indonesia's Mount Lewotobi Laki Laki erupted dramatically on June 18, generating substantial ash and smoke plumes....
MADRID, Spain: A routine oversight by Spain's power grid operator, REE, has been identified as the trigger behind the large-scale blackout...
WASHINGTON, DC - In a bid to defuse speculation, U.S. President Donald Trump says he will make his decision on whether to have the...
WASHINGTON, D.C.: A quiet shift inside the Trump administration has stalled a key diplomatic initiative aimed at pushing Russia toward...
NEW DELHI, India: Indian investigators are examining the black boxes from a Boeing 787 Dreamliner to determine the cause of a catastrophic...
NEW YORK, New YorK - U.S. stocks closed mixed on Friday, with gains and losses modest, as investors and traders weighed up the escalation...
WASHINGTON, D.C.: Retail sales dropped sharply in May as consumer spending slowed after a strong start to the year, primarily due to...
WASHINGTON, D.C.: Mitsubishi Motors is the latest automaker to raise prices in the United States, joining a growing list of car companies...
INDIANAPOLIS, Indiana: Eli Lilly is making a bold play in cardiovascular gene therapy, announcing plans to acquire its partner Verve...
BEIJING/WELLINGTON: New Zealand's Prime Minister Christopher Luxon commenced his visit to China on June 17, seeking to strengthen trade...
NEW YORK, New York - U.S. stocks made only minor moves in both directions,Thursday, as investors fretted about the Israel-Iran conflict...